<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="MEDLINE" Owner="NLM">        <PMID Version="1">30103904</PMID>        <DateCompleted>            <Year>2018</Year>            <Month>09</Month>            <Day>28</Day>        </DateCompleted>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>01</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1769-6917</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>105</Volume>                    <Issue>9</Issue>                    <PubDate>                        <Year>2018</Year>                        <Month>Sep</Month>                    </PubDate>                </JournalIssue>                <Title>Bulletin du cancer</Title>                <ISOAbbreviation>Bull Cancer</ISOAbbreviation>            </Journal>            <ArticleTitle>[5-fluorouracil therapeutic drug monitoring: Update and recommendations of the STP-PT group of the SFPT and the GPCO-Unicancer].</ArticleTitle>            <Pagination>                <MedlinePgn>790-803</MedlinePgn>            </Pagination>            <ELocationID EIdType="pii" ValidYN="Y">S0007-4551(18)30195-4</ELocationID>            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.bulcan.2018.06.008</ELocationID>            <Abstract>                <AbstractText>Despite being 60-years old now, 5-FU remains the backbone of numerous regimen to treat a variety of solid tumors such as breast, head-and-neck and digestive cancers either in neo-adjuvant, adjuvant or metastatic settings. Standard 5-FU usually claims 15-40% of severe toxicities and up to 1% of toxic-death. Numerous studies show a stiff relationship between 5-FU exposure and toxicity or efficacy. In addition, 5-FU pharmacokinetics is highly variable between patients. Indeed, 80% of the 5-FU dose is catabolized in the liver by dihydropyrimidine dehydrogenase (DPD) into inactive compounds. It is now well established that DPD deficiency could lead to severe toxicities and, thus, require dose reduction in deficient patients. However, despite dosage adaptation based on DPD status, some patients may still experience under- or over-exposure, leading to inefficacy or major toxicity. The &quot;Suivi thérapeutique pharmacologique et personnalisation des traitements&quot; (STP-PT) group of the &quot;Société française de pharmacologie et de thérapeutique&quot; (SFPT) and the &quot;Groupe de pharmacologie clinique oncologique&quot; (GPCO)-Unicancer, based on the latest and most up-to-date literature data, recommend the implementation of 5-FU Therapeutic Drug Monitoring in order to ensure an adequate 5-FU exposure.</AbstractText>                <CopyrightInformation>Copyright © 2018 Société Française du Cancer. Published by Elsevier Masson SAS. All rights reserved.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Lemaitre</LastName>                    <ForeName>Florian</ForeName>                    <Initials>F</Initials>                    <AffiliationInfo>                        <Affiliation>Université Rennes 1, CHU de Rennes, centre d'investigation clinique Inserm 1414, service de pharmacologie clinique, laboratoire de pharmacologie expérimentale et clinique, 2, rue Henri-Le-Guilloux, 35000 Rennes, France.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Goirand</LastName>                    <ForeName>Françoise</ForeName>                    <Initials>F</Initials>                    <AffiliationInfo>                        <Affiliation>Centre hospitalo-universitaire de Dijon-Bourgogne, 5, boulevard Jeanne-d'Arc, 21000 Dijon, France.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Launay</LastName>                    <ForeName>Manon</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Hôpital européen Georges-Pompidou, laboratoire de pharmacologie et de toxicologie, service de pharmacologie, 20, rue Leblanc, 75908 Paris cedex 15, France.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Chatelut</LastName>                    <ForeName>Etienne</ForeName>                    <Initials>E</Initials>                    <AffiliationInfo>                        <Affiliation>Institut Claudius-Regaud et centre de recherches en cancérologie de Toulouse, IUCT - Oncopole, 1, avenue Irène-Joliot-Curie, 31059 Toulouse, France.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Boyer</LastName>                    <ForeName>Jean-Christophe</ForeName>                    <Initials>JC</Initials>                    <AffiliationInfo>                        <Affiliation>CHU de Nîmes Carémeau, laboratoire de biochimie et biologie moléculaire, place du Professeur-Robert-Debré, 30029 Nîmes cedex 9, France.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Evrard</LastName>                    <ForeName>Alexandre</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>CHU de Nîmes Carémeau, laboratoire de biochimie et biologie moléculaire, place du Professeur-Robert-Debré, 30029 Nîmes cedex 9, France.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Paludetto</LastName>                    <ForeName>Marie-Noelle</ForeName>                    <Initials>MN</Initials>                    <AffiliationInfo>                        <Affiliation>Institut Claudius-Regaud et centre de recherches en cancérologie de Toulouse, IUCT - Oncopole, 1, avenue Irène-Joliot-Curie, 31059 Toulouse, France.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Guilhaumou</LastName>                    <ForeName>Romain</ForeName>                    <Initials>R</Initials>                    <AffiliationInfo>                        <Affiliation>AP-HM, CHU Timone, service de pharmacologie clinique et pharmacovigilance, 264, rue Saint-Pierre, 13005 Marseille, France.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Ciccolini</LastName>                    <ForeName>Joseph</ForeName>                    <Initials>J</Initials>                    <AffiliationInfo>                        <Affiliation>AP-HM, CHU Timone, SMARTc CRCM UMR Inserm U1068, laboratoire de pharmacocinétique clinique, 265, rue St-Pierre, 13385 Marseille, France.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Schmitt</LastName>                    <ForeName>Antonin</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>Centre Georges-François-Leclerc, service pharmacie, 1, rue Pr.-Marion, 21000 Dijon, France. Electronic address: aschmitt@cgfl.fr.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>fre</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>                <PublicationType UI="D016454">Review</PublicationType>            </PublicationTypeList>            <VernacularTitle>Suivi thérapeutique pharmacologique du 5-fluorouracile : mise au point et recommandations du groupe STP-PT de la SFPT et du GPCO-Unicancer.</VernacularTitle>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>08</Month>                <Day>10</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>France</Country>            <MedlineTA>Bull Cancer</MedlineTA>            <NlmUniqueID>0072416</NlmUniqueID>            <ISSNLinking>0007-4551</ISSNLinking>        </MedlineJournalInfo>        <ChemicalList>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D000964">Antimetabolites, Antineoplastic</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>EC 1.3.1.2</RegistryNumber>                <NameOfSubstance UI="D042943">Dihydrouracil Dehydrogenase (NADP)</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>U3P01618RT</RegistryNumber>                <NameOfSubstance UI="D005472">Fluorouracil</NameOfSubstance>            </Chemical>        </ChemicalList>        <CitationSubset>IM</CitationSubset>        <MeshHeadingList>            <MeshHeading>                <DescriptorName UI="D000964" MajorTopicYN="N">Antimetabolites, Antineoplastic</DescriptorName>                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>                <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>                <QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D054067" MajorTopicYN="N">Dihydropyrimidine Dehydrogenase Deficiency</DescriptorName>                <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D042943" MajorTopicYN="N">Dihydrouracil Dehydrogenase (NADP)</DescriptorName>                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D016903" MajorTopicYN="N">Drug Monitoring</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D005472" MajorTopicYN="N">Fluorouracil</DescriptorName>                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>                <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>                <QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName>                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D011110" MajorTopicYN="N">Polymorphism, Genetic</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D017410" MajorTopicYN="N">Practice Guidelines as Topic</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D012955" MajorTopicYN="N">Societies, Medical</DescriptorName>            </MeshHeading>        </MeshHeadingList>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">5-fluorouracile</Keyword>            <Keyword MajorTopicYN="N">Fluoropyrimidine</Keyword>            <Keyword MajorTopicYN="N">Pharmacocinétique</Keyword>            <Keyword MajorTopicYN="N">Pharmacokinetics</Keyword>            <Keyword MajorTopicYN="N">Recommandation</Keyword>            <Keyword MajorTopicYN="N">Suivi thérapeutique pharmacologique</Keyword>            <Keyword MajorTopicYN="N">Therapeutic drug monitoring</Keyword>            <Keyword MajorTopicYN="N">Toxicity</Keyword>            <Keyword MajorTopicYN="N">Toxicité</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>05</Month>                <Day>04</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="revised">                <Year>2018</Year>                <Month>06</Month>                <Day>13</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>06</Month>                <Day>14</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>8</Month>                <Day>15</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>3</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>8</Month>                <Day>15</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30103904</ArticleId>            <ArticleId IdType="pii">S0007-4551(18)30195-4</ArticleId>            <ArticleId IdType="doi">10.1016/j.bulcan.2018.06.008</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>